

Lao PDR

Support for Vaccine: IPV

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lao PDR																						
2. Vaccine grant number:		15-LAO-08h-Y, 1518-LAO-25b-X, 19-LAO-25b-X																				
3. Date of Decision Letter:		7-Jun-19																				
4. Date of the Partnership Framework Agreement:		7-Jun-13																				
5. Programme title:		New Vaccine Support (NVS), IPV, Routine																				
6. Vaccine type:		IPV																				
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID																						
8. Programme Duration:¹		2015-2019																				
9. Programme Budget (indicative):²		(subject to the terms of the Partnership Framework Agreement, if applicable)																				
	2015-2018	2019	2020	2021	2022	2023	Total ²															
Programme Budget (US\$)	1,311,461	464,500	-	-	-	-	1,775,961															
10. Vaccine introduction grant:																						
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount</th> </tr> </thead> <tbody> <tr> <td>2015</td> <td>15-LAO-08h-Y</td> <td>145,000</td> </tr> </tbody> </table> <table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>24 October, 2014</td> <td>145,000</td> </tr> </tbody> </table>								Approval			Year	Grant Number	Amount	2015	15-LAO-08h-Y	145,000	Disbursement		Disbursement date	Amount (US\$)	24 October, 2014	145,000
Approval																						
Year	Grant Number	Amount																				
2015	15-LAO-08h-Y	145,000																				
Disbursement																						
Disbursement date	Amount (US\$)																					
24 October, 2014	145,000																					
11. Product switch grant:																						
Not applicable																						
12. Indicative Annual Amounts:³		(subject to the terms of the Partnership Framework Agreement, if applicable)																				
Type of supplies to be purchased with Gavi funds	2015-2018	2019	2020																			
Number of vaccine doses		155,600	-																			
Annual Amounts (US\$)	1,311,461	464,500	-																			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the total amount approved by Gavi.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.													
14. Self-procurement:	Not applicable													
15. Co-financing obligations:	<p>Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>													
16. Operational support for catch-up campaigns:	Not applicable													
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</td> <td></td> </tr> <tr> <td> <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; </td> <td>31 March 2019</td> </tr> <tr> <td> <ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. </td> <td>15 May 2019</td> </tr> <tr> <td> <ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td></td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		<ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; 	31 March 2019	<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May 2019	<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 		In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates													
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:														
<ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; 	31 March 2019													
<ul style="list-style-type: none"> Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May 2019													
<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat													
18. Financial clarifications:	Not applicable													
19. Other conditions:	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>													

Signed by,

On behalf of Gavi



Hind Khatib-Othman

Managing Director, Country Programmes

7 June 2019